Hull University Teaching Hospitals NHS Trust
Hull, HU3 2JZ, United Kingdom
Location status: Recruiting
NCT Number: NCT07270562
ORACLE is a Europe-wide study that will follow 250 people with critical limb-threatening ischemia (CLTI). It aims to see how well orbital atherectomy (OA) works in real-life practice. OA is a procedure that uses a tiny spinning tool to gently remove hard calcium from inside an artery, helping to open the vessel so other treatments-like balloons or stents-can work better. The study focuses on people who have heavily calcified arteries in the femoropopliteal or infrapopliteal areas of the leg.
Interested in participating?
Request Info18 year and older
All sexes
Observational
Hull, HU3 2JZ, United Kingdom
Location status: Recruiting
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The Stealth 360™ Peripheral Orbital Atherectomy System uses a diamond-coated, eccentrically mounted crown with bi-directional capabilities that treat a wide range of vessels, enabling single device treatment of multiple lesions and vessel sizes.
Other names: Orbital Atherectomy, Orbital Atherectomy System
Time frame: Immediately after procedure completion
Defined as residual stenosis ≤30%, immediately after completion of full planned procedure (OA + any planned adjunctive intervention(s)).
Time frame: Immediately after procedure completion
Defined as residual stenosis ≤30% immediately after completion of additional unplanned endovascular intervention(s) (any endovascular procedure that was not part of the primary procedure plan).
Time frame: Immediately after procedure completion
Defined as any stent placement that was not part of the primary procedure plan.
Time frame: 12 and 24 months
Defined as freedom from any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion.
Time frame: Until the end of the follow-up period of 2 years
Defined as time between first OA procedure and any endovascular re-intervention to the target lesion (± 10 mm) or surgical bypass performed because of restenosis or occlusion of the target lesion.
Time frame: 12 and 24 months
The Rutherford classification is a clinical scale used to categorize the severity of peripheral arterial disease: Category 0 = asymptomatic; Category 1 = mild claudication; Category 2 = moderate claudication; Category 3 = severe claudication; Category 4 = ischemic rest pain; Category 5 = minor tissue loss; Category 6 = severe tissue loss.
Time frame: 12 and 24 months
Defined as healing status of the dominant ischemic wound of the target limb (complete, partial, unchanged, worsening).
Time frame: 12 and 24 months
Defined as absence of any amputation of the target limb (above ankle).
Time frame: Until the end of the follow-up period of 2 years
Defined as time between first OA procedure and above-ankle amputation of the target limb.
Time frame: Until the end of the follow-up period of 2 years
Defined as the time between the first OA procedure and death of any cause.
Time frame: Baseline, 6, 12 and 24 months post treatment
Measured by Vascular Quality of Life Questionnaire - 6 items (VascuQol-6), which is a short patient-reported outcome measure (PROM), used to assess health-related quality of life in people with PAD. It consists of 6 questions, each scored from 1 to 7, with 1 as the worst possible quality of life and 7 as the best possible quality of life. Higher overall scores reflect better quality of life for patients with PAD.
Time frame: Within 30 days after the OA procedure
Grading according to the classification system of the Cardiovascular and Interventional Radiological Society of Europe.
Time frame: 12 and 24 months
The ankle-brachial index (ABI) is a non-invasive measure calculated as the ratio of systolic blood pressure at the ankle to systolic blood pressure at the arm. ABI categories commonly used to classify peripheral arterial disease are: >1.40 = non-compressible arteries; 1.00-1.40 = normal; 0.91-0.99 = borderline; 0.41-0.90 = mild to moderate peripheral arterial disease; <0.40 = severe peripheral arterial disease.
Time frame: 12 and 24 months
The toe pressure test measures distal limb perfusion by recording systolic pressure at the toe. In CLTI patients, toe pressure ≤30 mmHg is commonly used to indicate severe ischemia, while values >30 mmHg suggest better perfusion.
Time frame: 12 and 24 months
The WIfI classification is a staging system used to assess CLTI based on wound extent, ischemia severity, and foot infection. Each component is graded from 0 (none) to 3 (severe). Lower WIfI scores indicate a lower risk of limb loss and a lesser urgency for revascularization, whereas higher scores indicate greater disease severity, higher amputation risk, and greater potential benefit from revascularization.
Interested in participating?
Request InfoCardiovascular and Interventional Radiological Society of Europe
Other
Acronym: ORACLE
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07270575
Arterial Occlusive Diseases, Arteriosclerosis
Hull, United Kingdom
View Trial DetailsNCT07472049
Arterial Occlusive Diseases, Arteriosclerosis
Edinburgh, Midlothian, United Kingdom
View Trial DetailsNCT06979284
Arterial Occlusive Diseases, Arteriosclerosis
Hamilton, Canada
View Trial DetailsNCT07465627
Arterial Occlusive Diseases, Arteriosclerosis
Graz, Austria
View Trial Details